CODEX DNA INC (DNAY) Stock Price & Overview

NASDAQ:DNAY • US1920031010

Current stock price

1.3 USD
+0.1 (+8.33%)
Last:

The current stock price of DNAY is 1.3 USD. Today DNAY is up by 8.33%. In the past month the price decreased by -5.8%. In the past year, price decreased by -86.13%.

DNAY Key Statistics

52-Week Range1.0801 - 11.02
Current DNAY stock price positioned within its 52-week range.
1-Month Range1.0801 - 1.43
Current DNAY stock price positioned within its 1-month range.
Market Cap
38.378M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.80
Dividend Yield
N/A

DNAY Stock Performance

Today
+8.33%
1 Week
+4.84%
1 Month
-5.80%
3 Months
-16.13%
Longer-term
6 Months -37.20%
1 Year -86.13%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

DNAY Stock Chart

CODEX DNA INC / DNAY Daily stock chart

DNAY Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to DNAY. When comparing the yearly performance of all stocks, DNAY is a bad performer in the overall market: 94.18% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

DNAY Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to DNAY. DNAY may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

DNAY Earnings

Next Earnings DateN/A
Last Earnings DateNov 8, 2022
PeriodQ3 / 2022
EPS Reported-$0.42
Revenue Reported
EPS Surprise 14.22%
Revenue Surprise 23.47%

DNAY Forecast & Estimates

9 analysts have analysed DNAY and the average price target is 6.63 USD. This implies a price increase of 410% is expected in the next year compared to the current price of 1.3.

For the next year, analysts expect an EPS growth of -6.4% and a revenue growth 106.09% for DNAY


Analysts
Analysts84.44
Price Target6.63 (410%)
EPS Next Y-6.4%
Revenue Next Year106.09%

DNAY Groups

Sector & Classification

Index Membership

DNAY Financial Highlights

Over the last trailing twelve months DNAY reported a non-GAAP Earnings per Share(EPS) of -1.8. The EPS decreased by -63.94% compared to the year before.


Income Statements
Revenue(TTM)21.04M
Net Income(TTM)-52.83M
Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity 0.37
Chartmill High Growth Momentum
EPS Q2Q%-23.53%
Sales Q2Q%139.59%
EPS 1Y (TTM)-63.94%
Revenue 1Y (TTM)112.52%

DNAY Ownership

Ownership
Inst Owners0.08%
Shares29.52M
Float8.59M
Ins Owners28.32%
Short Float %N/A
Short RatioN/A

About DNAY

Company Profile

DNAY logo image Codex DNA, Inc. engages in research and development of genomic tools for biomedical and industrial applications. The company is headquartered in San Diego, California and currently employs 212 full-time employees. The company went IPO on 2021-06-18. Its synthetic biology solution addresses bottlenecks across the multi-step process of building DNA and mRNA, as well as the limitations of existing solutions that prevent the building of DNA and mRNA at a useable scale. Its BioXp system is an end-to-end automated workstation. The firm's products include BioXp systems, including BioXp 3250 system, BioXp kits for generating a range of synthetic DNA and mRNA, and benchtop reagents that complement the automated synthetic biology workflow applications and workflow solutions. The company has launched eight BioXp kits, three benchtop reagent kits, and various other synthetic biology products, including 14 SARS-CoV-2 full-length genomes and RNA controls, as well as its Vmax X2 cells. The company has placed approximately 200 BioXp systems globally.

Company Info

IPO: 2021-06-18

CODEX DNA INC

9535 Waples Street, Suite 100

San Diego CALIFORNIA US

CEO: Todd R. Nelson

Employees: 212

DNAY Company Website

Phone: 18582284115.0

CODEX DNA INC / DNAY FAQ

What does CODEX DNA INC do?

Codex DNA, Inc. engages in research and development of genomic tools for biomedical and industrial applications. The company is headquartered in San Diego, California and currently employs 212 full-time employees. The company went IPO on 2021-06-18. Its synthetic biology solution addresses bottlenecks across the multi-step process of building DNA and mRNA, as well as the limitations of existing solutions that prevent the building of DNA and mRNA at a useable scale. Its BioXp system is an end-to-end automated workstation. The firm's products include BioXp systems, including BioXp 3250 system, BioXp kits for generating a range of synthetic DNA and mRNA, and benchtop reagents that complement the automated synthetic biology workflow applications and workflow solutions. The company has launched eight BioXp kits, three benchtop reagent kits, and various other synthetic biology products, including 14 SARS-CoV-2 full-length genomes and RNA controls, as well as its Vmax X2 cells. The company has placed approximately 200 BioXp systems globally.


What is the stock price of CODEX DNA INC today?

The current stock price of DNAY is 1.3 USD. The price increased by 8.33% in the last trading session.


What is the dividend status of CODEX DNA INC?

DNAY does not pay a dividend.


How is the ChartMill rating for CODEX DNA INC?

DNAY has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


How is the market expecting DNAY stock to perform?

9 analysts have analysed DNAY and the average price target is 6.63 USD. This implies a price increase of 410% is expected in the next year compared to the current price of 1.3.


What is the expected growth for DNAY stock?

The Revenue of CODEX DNA INC (DNAY) is expected to grow by 106.09% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


Can you provide the number of employees for CODEX DNA INC?

CODEX DNA INC (DNAY) currently has 212 employees.